导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.56% | 2663/4773 |
| 近一周 | -0.63% | 221/5462 |
| 近一月 | 2.24% | 282/5421 |
| 近一季 | 2.62% | 448/5209 |
| 近半年 | -2.05% | 1761/4920 |
| 近一年 | 2.30% | 2148/4366 |
| 近两年 | 29.52% | 2290/2954 |
| 近三年 | 26.13% | 1227/2253 |
| 成立以来 | 140.78% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.55% 3278/4961 |
-5.20% 3547/5312 |
- - |
- - |
| 2025 | 9.16% 2879/4813 |
-1.89% 2811/3635 |
5.46% 586/4076 |
-0.82% 3942/4524 |
6.38% 364/4813 |
| 2024 | 27.47% 188/3463 |
8.64% 175/2808 |
3.65% 259/3014 |
14.07% 2051/3129 |
-0.76% 1512/3463 |
| 2023 | -0.95% 484/2656 |
3.56% 1167/2280 |
1.02% 250/2385 |
2.29% 241/2515 |
-7.45% 2154/2655 |
| 2022 | -9.91% 191/2207 |
-4.56% 166/1919 |
-0.45% 1625/2016 |
-8.26% 185/2113 |
3.36% 709/2208 |
| 2021 | 2.33% 634/1822 |
6.20% 97/1255 |
-3.03% 1235/1330 |
-1.07% 505/1466 |
0.45% 1109/1822 |
| 2020 | 7.32% 868/1250 |
-12.93% 906/1028 |
3.31% 944/1067 |
10.13% 585/1164 |
8.32% 679/1184 |
| 2019 | 25.73% 592/1092 |
18.45% 639/754 |
1.94% 105/804 |
-1.36% 648/850 |
5.55% 705/918 |
| 2018 | -14.69% 99/834 |
- - |
- - |
- - |
-10.51% 201/691 |
| 2017 | 36.29% 31/714 |
- - |
- - |
- - |
- - |
| 2016 | -2.43% 130/605 |
- - |
- - |
- - |
- - |
| 2015 | 5.05% 224/575 |
- - |
- - |
- - |
- - |
| 2014 | 60.71% 31/237 |
- - |
- - |
- - |
- - |
| 2013 | -8.90% 141/186 |
- - |
- - |
- - |
- - |
| 2012 | 14.59% 15/140 |
- - |
- - |
- - |
- - |
| 2011 | -16.39% 11/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 申万菱信沪深300价值指数A VS. 长安沪深300非周期A(740101) |